What Is KPV?

Overview

KPV is a short tripeptide built from the amino acids lysine, proline and valine — the sequence that gives it its name. It corresponds to the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), a signalling peptide that arises from proopiomelanocortin biology. Despite its minimal size, KPV retains much of the anti-inflammatory character associated with the parent hormone while shedding the pigmentary activity, which is why researchers studying mucosal and epithelial inflammation use it as a compact, well-defined probe.

How KPV Works

In laboratory models KPV appears to dampen pro-inflammatory signalling rather than acting on a single classical receptor. Investigations point to interference with the NF-kappaB transcriptional pathway, which governs the expression of many inflammatory genes, and to a downstream reduction in cytokines such as TNF, IL-1 beta and IL-6. A distinctive feature is that intestinal epithelial cells can take the intact tripeptide up through PEPT1 (peptide transporter 1), the carrier that normally shuttles di- and tri-peptides across the gut lining. That transport route is one reason KPV is frequently examined in colitis and barrier-function work, since it offers a plausible way for the peptide to reach the cells where inflammation is being modelled.

What the Research Explores

• Intestinal inflammation and experimental colitis models tied to inflammatory bowel disease.
• NF-kappaB signalling and the modulation of pro-inflammatory cytokine output.
• PEPT1-mediated epithelial uptake and intestinal barrier integrity.
• Skin inflammation pathways, including dermatitis and psoriasis-related mechanisms.
• Wound-healing and tissue-repair questions in pre-clinical settings.

Forms & Handling

For research purposes KPV is generally supplied as a lyophilized powder, commonly in a 10 mg vial. It is reconstituted with bacteriostatic or sterile water before laboratory use and kept refrigerated once dissolved, with the dry powder stored cold and away from light to preserve stability. The dosing protocol linked below works through the reconstitution math, including milligram-per-milliliter concentration and the corresponding insulin-syringe unit measurements.

Safety & Research Notes

KPV is an investigational research compound with no FDA-approved drug label, no standardized dosing, and no formal adverse-event profile of the kind established for approved medicines. The available literature is largely pre-clinical and mechanistic rather than drawn from large human trials, so questions around long-term use, pregnancy, and interactions with immunosuppressants or biologics remain unmapped. Everything described here is mechanistic background for laboratory study, not a usage recommendation.

References

Related Protocols